It was a great pleasure to be invited (thanks to our partner Molecular Devices) to present our work during these 2 events organized by selectBio in Rotterdam: Organoids and Tox Screening Europe 2019 on June 13-14 Organ-on-a-Chip and Tissue-on-a-Chip Europe 2019 on June 18-19 Both were of great interest for Read more…
In the continuity of our scientific reviews about the important roles of Hyaluronic Acid (HA) in extracellular matrix (ECM) and cell behavior, we herein present this recent review describing the structure – function relationship of HA. As an important polysaccharide of ECM, HA plays an important role in cell and Read more…
Last week we were pleased to attend the founding congress of STCM (Société de Toxicologie Cellularie et Moléculaire), which was held in FIAP Jean Monnet (Paris). The topic was “Toxicology towards the 3rd dimension“. With a wide variety of talks from academic laboratories and from the industry, the content was Read more…
The founding congress of the french STCM (Société de Toxicologie Cellulaire et Moléculaire) will take place in Paris at the end of this week (13th-14th June, 2019). The theme of this meeting will be “Toxicology towards the 3rd dimension“. We are looking forward to attending this congress, and to becoming Read more…
We will be present this week and next week in Rotterdam, to talk about 3D cell culture and the importance of the microenvironnement in the relevance of in vitro models. As you known, to mimic human tissues, several parameters need to be taken into account: the target cells, nutrient intake Read more…
The extracellular matrix (ECM) is a three-dimensional macromolecular network composed of structural proteins (collagens, elastin), adhesion/signalling proteins (fibronectin, laminins), different proteoglycans, glycoproteins and glycosaminoglycans (GAGs). GAGs are structurally complex, but their structure is simply made up of repeating disaccharide building blocks composed of alternating uronic acid and hexosamine units. GAGs Read more…
The 16th SFBMEC congress was held last week in Reims: Elodie and Zied attended the meeting to be aware of the last trends in extracellular matrix (ECM) research and industry and medical applications. And they were not disappointed! After a first touching lecture in memoriam of the late Ladislas Robert Read more…
Next week HCS Pharma will be present at SFBMEc Reims (15th-17th May). We will present a poster about the influence of BIOMIMESYS® hydroscaffold composition and stiffness on the 3D culture of breast cancer cells. The poster will be avalaible next week, but if you want it before, you can contact Read more…
Last week HCS Pharma team enjoyed Forum Labo Paris! We enjoyed it twofold because : we won our booth on the Lab’StartUp Village, in the heart of the fair. It gave us the opportunity to present our BIOMIMESYS® products! we won a price for our amazing photo of liver cells… Read more…
HCS Pharma is one of the winner of the Lab’StartUp village, organized by Forum Labo! As such, we have won a stand in the heart of the forum (March 26-28, 2019)… Thanks a lot to the committee for evaluating our application to this prize, and for selecting our new product Read more…
Most potential drug candidates (90%) fail within the clinical trials, mainly because of lack of efficacy. What if the pharmaceutical industry uses predictive human in vitro models in early drug discovery ? View and download on Slideshare (low quality) https://fr.slideshare.net/hcspharma/a-groundbreaking-3d-cell-culture-technology-for-hcs-biomimesys-hydroscaffold Ask for high quality link by putting your email below
We will be at the next edition of SLAS meeting in Washington, DC February 2nd and 3th. If you wish to meet us, we will welcome you on our partner’s booth, Molecular Devices (#437) We will talk about “Phenotypic screening in 3D culture including ECM: advantages and challenges” on Monday, Read more…
Many categories of drugs can induce hepatotoxicity, so improving the prediction of toxic drugs is important. In vitro models using human hepatocytes are more accurate than in vivo animal models. Good in vitro models require an abundance of metabolic enzyme activities and normal cellular polarity. However, none of the in Read more…
Cells have diverse circuitry to sense and respond to extrinsic metabolic signals. Extracellular matrix (ECM) reorganization which is central to both tissue expansion and regeneration. ECM remodeling is also a signature of pathological processes, such as tumorigenesis. In this study from Sullivan et al., they show that increased migration in Read more…
“Regulation needs to catch up with innovation.” Henry Paulson – CEO Goldman Sachs A very nice state of art about animal testing and its alternatives can be found in the new article “Animal Testing and its Alternatives – the Most Important Omics is Economics” from Hartung et al. This study established that Read more…
We had the pleasure to attend ELRIG Fr meeting in Bischoffsheim (near Strasbourg) on the 23-24th of May. There we enjoyed meeting our partners Molecular Devices and Integra biosciences, and seeing great presentations about the last trends in automation. Our collaborator Karim Si-Tayeb presented his amazing results regarding the differentiation Read more…
Interesting paper from Christian Dani team about the potential of Brown and brown-like adipocytes (BAs) proginitors derived from hiPSCs to dissipate energy stored and the promising potential to treat obesity and metabolic disorder. In this publication, they describe the capacity of human-induced pluripotent stem cells (hiPSCs) to generate BAPs able Read more…
Our new poster on BIOMIMESYS® technology is now avalaible on this link. It presents the use of this scaffold on our automated platform (Hapix), with the development of a 3D cell model for steatosis and phospholipidosis assessment as an example. Automated HepG2 cells seeding, medium renewal, spheroids treatment, fixation, staining and Read more…
The first EUROoC meeting, dealing with organ-on-chip research and organized by the Chemical and Biological Microsystems Society (CBMS), will take place on the 24th-25th of May 2018 in Stuttgart (Germany). Interestingly, this new workshop will address the engineering challenges related to the design, fabrication and implementation of organ-on-chips (OOC) and microphysiological systems. Among other Read more…
According to a report issued by the Tufts Center for the Study of Drug Development, the costs associated with bringing a novel drug to market exceed $2.5 billion per successful compound
#hcs by multiplexing assays on #3d cell culture have many advantages to find more efficient new drugs for #cancer treatment. Progress in the IT part, on softwares, on the uses on big data and in the machine on speed and sensitivity allow to do multiplexing assays in HCS . This article Read more…